Wilmington Savings Fund Society FSB Sells 15,167 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

Wilmington Savings Fund Society FSB cut its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 85.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,500 shares of the company's stock after selling 15,167 shares during the period. Wilmington Savings Fund Society FSB's holdings in Revolution Medicines were worth $109,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Citigroup Inc. lifted its stake in Revolution Medicines by 29.5% during the third quarter. Citigroup Inc. now owns 117,938 shares of the company's stock valued at $5,348,000 after purchasing an additional 26,871 shares during the last quarter. State Street Corp lifted its stake in Revolution Medicines by 4.1% during the third quarter. State Street Corp now owns 5,279,584 shares of the company's stock valued at $239,429,000 after purchasing an additional 208,516 shares during the last quarter. Barclays PLC lifted its stake in Revolution Medicines by 187.1% during the third quarter. Barclays PLC now owns 294,664 shares of the company's stock valued at $13,362,000 after purchasing an additional 192,021 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Revolution Medicines by 58.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,763,117 shares of the company's stock valued at $79,957,000 after purchasing an additional 653,433 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Revolution Medicines by 1,109.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 38,589 shares of the company's stock valued at $1,750,000 after purchasing an additional 35,399 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, COO Margaret A. Horn sold 4,329 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $45.40, for a total transaction of $196,536.60. Following the transaction, the chief operating officer now owns 127,991 shares in the company, valued at $5,810,791.40. This represents a 3.27 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Jack Anders sold 2,635 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $119,629.00. Following the transaction, the chief financial officer now owns 96,470 shares in the company, valued at approximately $4,379,738. This trade represents a 2.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,678 shares of company stock worth $847,981 in the last quarter. 8.00% of the stock is currently owned by corporate insiders.

Revolution Medicines Trading Down 1.6 %

RVMD stock traded down $0.65 during midday trading on Monday, reaching $40.67. The company had a trading volume of 1,461,401 shares, compared to its average volume of 1,412,222. Revolution Medicines, Inc. has a 1 year low of $28.43 and a 1 year high of $62.40. The company has a market capitalization of $6.84 billion, a P/E ratio of -11.33 and a beta of 1.45. The company has a 50 day moving average of $42.95 and a two-hundred day moving average of $46.36.

Analyst Ratings Changes

Several analysts recently commented on the stock. Guggenheim increased their target price on shares of Revolution Medicines from $82.00 to $87.00 and gave the company a "buy" rating in a research note on Tuesday, December 3rd. UBS Group upped their price target on shares of Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Oppenheimer upped their price target on shares of Revolution Medicines from $55.00 to $60.00 and gave the company an "outperform" rating in a research report on Monday, October 28th. JPMorgan Chase & Co. upped their price target on shares of Revolution Medicines from $63.00 to $71.00 and gave the company an "overweight" rating in a research report on Tuesday, December 3rd. Finally, HC Wainwright upped their price target on shares of Revolution Medicines from $64.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, December 4th. Eleven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $66.25.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.